

1 **Tenogenic differentiation of human embryonic stem cells**

2

3 Tina P Dale, PhD <sup>(1)</sup>, Shazia Mazher, BSc <sup>(1)</sup>, William R Webb, PhD <sup>(1)</sup>, Jing Zhou, MSc <sup>(2)</sup>,  
4 Nicola Maffulli, MD, PhD <sup>(3)</sup>, Guo-Qiang Chen, PhD <sup>(2)</sup>, Alicia J El Haj, PhD <sup>(1)</sup> and Nicholas R  
5 Forsyth, PhD<sup>(1,4)</sup>

6

7 <sup>(1)</sup> Guy Hilton Research Centre, Keele University, Thornburrow Drive, Stoke-on-Trent ST4  
8 7QB, UK.

9 Tel. +44 (0) 1782 674 087

10 Dr Tina Dale – [t.p.dale@keele.ac.uk](mailto:t.p.dale@keele.ac.uk)

11 Ms Shazia Mazher - [shaziamazher452@hotmail.com](mailto:shaziamazher452@hotmail.com)

12 Dr William R Webb - [william\\_r\\_webb@sky.com](mailto:william_r_webb@sky.com)

13 Prof Alicia J El Haj – [a.j.el.haj@keele.ac.uk](mailto:a.j.el.haj@keele.ac.uk)

14 Prof Nicholas R Forsyth – [n.r.forsyth@keele.ac.uk](mailto:n.r.forsyth@keele.ac.uk)

15

16 <sup>(2)</sup> School of Life Science, Tsinghua University, Beijing, 100084, China.

17 Tel: +86 10 62783844

18 Dr Jing Zhou - [jingzhou2010@gmail.com](mailto:jingzhou2010@gmail.com)

19 Professor Guo-Qiang Chen - [chengq@mail.tsinghua.edu.cn](mailto:chengq@mail.tsinghua.edu.cn)

20

21 <sup>(3)</sup> Centre for Sport & Exercise Medicine, Queen Mary, University of London, UK.

22 + 44 20 8223 8839

23 [n.maffulli@qmul.ac.uk](mailto:n.maffulli@qmul.ac.uk)

24 <sup>(4)</sup> Corresponding author

25

26 **Abstract**

27 Tendon healing is complex to manage because of the limited regeneration capacity of tendon  
28 tissue; stem cell-based tissue engineering approaches may provide alternative healing  
29 strategies. We sought to determine whether human embryonic stem cells (hESC) could be  
30 induced to differentiate into tendon-like cells by the addition of exogenous bone morphogenetic  
31 protein (BMP)12 (growth differentiation factor(GDF)7) and BMP13 (GDF6). hESC (SHEF-1)  
32 were maintained with or without BMP12/13 supplementation, or supplemented with  
33 BMP12/13 and the SMAD signalling cascade blocking agent, dorsomorphin. Primary rat  
34 tenocytes were included as a positive control in immunocytochemistry analysis. A  
35 tenocyte-like elongated morphology was observed in hESC after 40-days continuous  
36 supplementation with BMP12/13 and ascorbic acid. These cells displayed a tenomodulin  
37 expression pattern and morphology consistent with that of the primary tenocyte control.  
38 Analysis of tendon-linked gene transcription in BMP12/13 supplemented hESC demonstrated  
39 consistent expression of *COL1A2*, *COL3A1*, *DCN*, *TNC*, *THBS4*, and *TNMD* levels.  
40 Conversely, when hESCs were cultured in the presence of BMP12/13 and dorsomorphin  
41 *COL3A1*, *DCN*, and *TNC* gene expression and tendon matrix formation were inhibited. Taken  
42 together, we have demonstrated that hESCs are responsive to tenogenic induction via  
43 BMP12/13 in the presence of ascorbic acid. The directed *in vitro* generation of tenocytes from  
44 pluripotent stem cells may facilitate the development of novel repair approaches for this  
45 difficult to heal tissue.

46

47 **Introduction**

48 Tendon is a major component of the musculoskeletal system (1) playing a vital role in force  
49 transmission between bone and muscle and enhancing joint stability (2). Acute trauma, overuse  
50 and ageing can lead to tendon injuries (3,4). Current treatments have limited capacity to achieve  
51 successful tendon healing since the tissue is poorly vascularized, and scar tissue or fibrous  
52 adhesions often develop during the healing process (5). Treatment can involve many different  
53 types of surgical intervention, such as xenograft or allograft to treat large tendon defects, but  
54 potential problems with this method (such as foreign body reaction) can occur (3). A lack of  
55 adequate strategies for tendon repair has led to the development of engineered replacement  
56 tendon tissue for use in surgical implantation (4). Stem cell based intervention may provide new  
57 strategies for tendon repair. Embryonic stem cells (hESCs) are derived from human blastocysts  
58 and due to telomerase activity self-renew indefinitely. Effectively the cells are immortal in  
59 culture, a property unique amongst the cell types with potential in regenerative medicine  
60 applications, providing cells in unlimited numbers. Furthermore, they are pluripotent and  
61 accordingly can differentiate into cells of all three embryonic germ layers, namely mesoderm,  
62 ectoderm and endoderm (6) conferring upon them potential across the whole field of  
63 regenerative medicine. Consequently, they are favoured for tissue engineering in therapeutic  
64 applications both *in vitro* and *in vivo* (7–9).

65

66 hESC are considered a valuable resource due to their intrinsic plasticity in differentiation  
67 capacity. However, there is a surprising paucity of research describing *in vitro* directed  
68 tenogenic differentiation of hESC. To date reports have favoured the engineering and rolling of

69 cell sheets derived from connective tissue growth factor (CTGF)-supplemented hESC-derived  
70 mesenchymal stem cells (hMSC) (10,11). These sheets then progress to display tendon-like  
71 morphological appearances, the expression of genes including *SCX*, *COL3A1*, and *DCN*, but  
72 not *TNMD* (12).

73

74 Bone morphogenic proteins 12 and 13 (BMP12/13, also known as GDF7/6) are members of the  
75 TGF- $\beta$  superfamily, and have individually been shown to play important roles in chemotaxis,  
76 proliferation, matrix synthesis, and cell differentiation (13–17). BMP12 and/or BMP13  
77 promote tendon repair in rats and sheep (13,18,19). In addition, BMP12 has been reported to  
78 induce the *in vitro* and *in vivo* tenogenesis of MSCs (derived from a wide variety of sources  
79 including bone marrow, synovial fluid, adipose tissue) in dog, mouse, rat, rhesus monkey,  
80 human, horse and chicken (13,20–28). There are also reports describing a role for BMP12 in  
81 tenogenic differentiation of tendon stem cells derived from rat (29). However, to our  
82 knowledge, there are no descriptions of the use of BMP12 and/or BMP13 to direct  
83 differentiation of hESCs into tendon-like cells. In this study, we investigated whether hESCs  
84 could differentiate into tenocyte-like cells when supplemented with BMP12/13 and ascorbic  
85 acid (AA). Further, we sought to determine whether SMAD signalling was implicated in  
86 BMP12/13 induced changes via inhibition of the SMAD pathway, or whether other signalling  
87 cascades were involved in the hESC tenogenic process.

88 **Materials and Methods**

89 *Culture of Primary Rat tenocytes and hESCs*

90 Primary tenocytes were isolated from 8 week old Sprague-Dawley rats. The Achilles tendon  
91 was isolated, extracted, placed into a dry petri dish and allowed to adhere for 3 hours. Media  
92 was added, and the explant cultured for 7 days allowing for tenocyte migration and expansion  
93 in ambient oxygen (21% O<sub>2</sub>)/5% CO<sub>2</sub> in high glucose Dulbecco's Modified Eagle Medium  
94 (DMEM, Lonza) supplemented with 10% fetal bovine serum (FBS, Lonza), 1% non-essential  
95 amino acids (NEAA, Lonza), 1% L-glutamine (Lonza) and 1% penicillin, streptomycin and  
96 amphotericin B (PSA, Lonza). After 7 days, the rat tenocytes were washed twice with  
97 phosphate buffered saline (PBS, Lonza), trypsinised (1% Trypsin/EDTA (Lonza)/PBS  
98 solution), centrifuged for 3 minutes (200g), re-seeded into two T-25 culture flasks, and cultured  
99 until 70% confluent. Once 70% confluent, the tenocytes were again trypsinised, and re-seeded  
100 at  $0.5 \times 10^3$  cells/cm<sup>2</sup> onto 6 well plates and cultured for a further 48 hours before being fixed for  
101 immunocytochemistry.

102

103 hESC were cultured according to the Matrigel substrate and mouse embryonic fibroblast  
104 (MEF)-conditioned media (CM) protocol (30). CM was obtained by placing Knockout  
105 (KO)-DMEM (Gibco), 20% Serum Replacent (SR) (Gibco), 1% NEAA, 1% L-Glutamine,  
106 4ng/ml bFGF (Peprotech) and 50mM β-mercaptoethanol (Gibco) for 24 hours on 50-60%  
107 confluent MEFs. After 24 hours, the culture medium was removed, and 4ng/ml bFGF added  
108 prior to filtration. SHEF-1 hESCs were cultured in either ambient (21% O<sub>2</sub>) or physiological,  
109 low-oxygen (2% O<sub>2</sub>) conditions. Differentiation was performed in the 2% O<sub>2</sub> condition only.

110 ***Tenogenic differentiation of hESCs***

111 SHEF-1 cells were seeded into 6-well plates at ( $2 \times 10^3$  cells/cm<sup>2</sup>) in CM. After 24 hours CM  
112 was removed and replaced with differentiation media which consisted of KO-DMEM, 10%  
113 FBS, 1% NEAA, 1% L-glutamine, 50mM  $\beta$ -mercaptoethanol and 10mM AA (Sigma) with or  
114 without BMP12 (R & D Systems) and BMP13 (Peprotech) both at 10ng/ml. To evaluate the  
115 role of SMAD signalling in tenogenic differentiation, hESC were seeded and differentiated as  
116 above, with the exception that during differentiation hESC were further supplemented with  
117 1 $\mu$ M dorsomorphin (31,32) (Sigma).

118

119 ***Reverse transcription PCR (RT-PCR)***

120 RNA was collected from undifferentiated hESC at Day 0, and subsequently at Days 5, 10 and  
121 20 in the presence of differentiation media in both 2% O<sub>2</sub> and 21% O<sub>2</sub>. In addition to above  
122 RNA was collected from hESC in differentiation media supplemented with either BMP12/13 or  
123 BMP12/13/dorsomorphin supplementation at days 5, 10, 20 and 40. RNA was collected by first  
124 washing with PBS followed by the addition of cell lysis buffer (Qiagen), scraping, collection,  
125 and homogenisation with a QIAshredder spin column (Qiagen). RNA extraction was performed  
126 with the RNeasy Mini kit (Qiagen) following manufacturer's instructions. RT-PCR was  
127 performed with Superscript III One-Step HiFi RT-PCR kit (Invitrogen) again following  
128 manufacturer's instructions. The genes analysed were representative of a tenocyte-like  
129 phenotype and were *COL1A2*, *COL3A1*, *DCN*, *TNC*, *TNMD* and *THBS4* (33), primers used are  
130 shown in Table 1. *GAPDH* level was used as an internal control. Electrophoresis was

131 performed on 2% agarose gel (Gibco) at 100V for 1 hour. Gels were imaged on the Syngene  
132 Gel UV illuminator.

133

#### 134 ***Immunocytochemical analysis***

135 Cells were fixed in 95% methanol for 15 minutes before being washed with PBS. Cells were  
136 permeabilised with 0.5% Triton-X for 5 minutes, washed with PBS, and incubated in a 3%  
137 albumin solution (Sigma) for 1 hour at room temperature. Primary tenomodulin antibody  
138 (C-terminus) (SC98875, Santa Cruz Biotechnologies, Germany, 1:500 dilution in PBS) was  
139 then added to each well followed by a 30 minute incubation at 37°C and PBS washes.

140 Secondary antibody (SC2090 Santa Cruz Biotechnologies, Germany, 1:500 dilution in PBS)  
141 was then added to the appropriate wells followed by a further incubation at 37°C for 30 minutes,  
142 PBS washes, and DAPI (1:500 dilution, Sigma) counterstaining. Images were captured via  
143 appropriate filter sets on Nikon Eclipse T1 microscope using a Nikon DSi 1 camera.

144

#### 145 ***Histological analysis***

##### 146 *Alcian Blue staining*

147 Cells were fixed at Days 0, 2, 5, 10, 20 and 40 using 95% methanol for 15 minutes followed by  
148 PBS washes. Cells were then stained with Alcian blue (A3157-10G, Sigma Aldrich, UK) for 24  
149 hours at room temperature on an R100 Rotateck shaker (Luckham). After 24 hours, the Alcian  
150 blue solution was aspirated, and each well washed with sterile double filtered dH<sub>2</sub>O. Once all  
151 the excess Alcian blue stain had been removed, the plates were dried at room temperature  
152 before imaging on Nikon Eclipse TD100 inverted microscope.



153 *Masson's Trichrome Staining*

154 Wells were fixed at days 0, 2, 5, 10, 20 and 40 using 95% methanol for 15 minutes and washed  
155 twice with PBS. PBS was aspirated from the wells and Bouin's Solution (Sigma) added to  
156 completely cover the well base before being placed on the R100 Rotateck shaker (Luckham) for  
157 24 hours. After 24 hours Bouin's solution was aspirated and each well washed with double  
158 filtered H<sub>2</sub>O to remove residual Bouin's solution. The wells were then counterstained with  
159 Haematoxylin (Sigma) for 5 minutes before washing as before and applying Biebrich  
160 Scarlet-Acid Fuschin solution (Sigma) for 5 minutes, washing again, and incubating in fresh  
161 phosphotungstic/phosphomolybdic acid solution (PT/PMA) (Sigma, 25% (v/v) PT, 25% PMA  
162 and 50% dH<sub>2</sub>O) for 5 minutes at room temperature. Following incubation in the PT/PMA  
163 solution and its removal aniline blue solution (Sigma) was added, and the samples incubated at  
164 room temperature for 5 mins before removal and incubation in 1% acetic acid at room  
165 temperature for a further for 2 minutes before washing again and air drying for 24 hours.  
166 Images were collected on a Nikon Eclipse TD100 inverted microscope with a Canon EOS  
167 400D camera.

168 *Quantification*

169 Staining intensity of Alcian blue and Masson's Trichrome stained images was semi-quantified  
170 using ImageJ (34)[31]. All images were acquired at low magnification with identical  
171 microscope and camera settings and were acquired from the centre of stained wells to avoid  
172 user bias. To ensure that only regions positively stained with Alcian blue were considered,  
173 RGB images were first colour separated using the ImageJ colour deconvolution algorithm  
174 developed by Ruifrok and Johnston, with colour vectors determined by region of interest as

175 previously described (35)[32]. For Masson's trichrome staining, total image intensity was  
176 determined.

### 177 *Statistical Analysis*

178 The significance of difference between groups (n=6 per group) was determined by one-way  
179 ANOVA single factor one-tailed comparison analysis. A p value less than 0.05 was considered  
180 to indicate statistical significance. Data are presented as mean  $\pm$  standard deviation (SD). All  
181 statistical analysis was performed using Minitab® 16 (Minitab Inc., Pennsylvania, USA).

182

183 **Results**

184 ***BMP12/13 stimulated the expression of tendon-linked gene expression in hESCs***

185 SHEF-1 cells cultured in a 21% O<sub>2</sub> environment in differentiation media without BMP  
186 supplementation showed continued expression of *GAPDH*, *COL1A2*, and *TNC* over 20 days  
187 (Figure 1, Left panel). *COL3A1* and *DCN* expression was apparent by Day 10 and thereafter  
188 whereas *THBS4* displayed sequential downregulation over the 20 day timecourse. *TNMD*  
189 expression was not detected. Similarly, SHEF-1 cells cultured in 2% O<sub>2</sub> environment in  
190 differentiation media without BMP supplementation again showed continued expression of  
191 *GAPDH*, *COL1A2* and *TNC* over 20 days (Figure 1, Right panel). *TNMD* expression was noted  
192 on Day 5 only and *COL3A1* and *DCN* on Day 10. In contrast to the observed expression pattern  
193 in 21% O<sub>2</sub>, *THBS4* underwent sequential upregulation of expression in 2% O<sub>2</sub>.

194

195 SHEF-1 treated with BMP12/13 over 40 days in 2% O<sub>2</sub> resulted in continuous expression of  
196 *GAPDH*, *COL1A2*, *COL3A1*, *TNC*, and *THBS4*. *DCN* underwent an apparent upregulation over  
197 the first 20 days while *TNMD* expression was maintained to Day 20 and reduced thereafter  
198 (Figure 2A Left panel). Differentiation media supplemented with both BMP12/13 and  
199 dorsomorphin showed several distinct differences when compared to BMP12/13 supplemented  
200 differentiation media (Figure 2A ). *COL3A1*, *DCN*, and *TNC* all underwent substantial  
201 downregulation of expression, whereas *COL1A2*, *THBS4*, and *TNMD* transcripts displayed  
202 sustained expression throughout the timecourse.

203

204

205 ***BMP-12/13 induced tenomodulin expression in hESCs***

206 SHEF-1 cells cultured in BMP12/13 supplemented differentiation media displayed little or no  
207 tenomodulin protein expression over the first 20 days (Figure 2C). However, by Day 40  
208 differentiated cells displayed a distinct tenomodulin staining pattern (Figure 2C), consistent  
209 with the synapsing observed with the rat tenocyte positive control (Figure 2B). The addition of  
210 dorsomorphin to BMP12/13 supplemented differentiation media resulted in an absence of  
211 observable tenomodulin staining over the timecourse (Figure 2C).

212

213 **Histological staining and colorimetric quantification**

214 **Alcian blue**

215 Tendon matrix is comprised primarily of collagen alongside a number of other matrix  
216 molecules including glycosaminoglycans (GAGs) (33). We next sought to determine the role of  
217 BMP12/13 in altering matrix composition towards a tendon-like GAG-rich composition. The  
218 histological stain Alcian blue revealed strong staining after 40 days differentiation vs. control  
219 cultures (Figure 3A). Visually Alcian blue positive regions appeared to associate into long,  
220 string-like, condensations which appeared to connect with each other. Primary rat tenocyte  
221 cultures (images included for observation) did not display histologically detectable GAG  
222 deposition in controls or in response to BMP12/13 supplementation and were therefore not  
223 quantified. Over 40 days untreated control hESC displayed an approximate 21% increase in  
224 positive labelling whereas samples incubated with BMP12/13 registered a 35% increase  
225 (Figure 4A). This indicated a spontaneous deposition of GAGs in control hESC cultures that  
226 was significantly augmented by BMP12/13 supplementation. Dorsomorphin addition to control

227 hESC cultures resulted in a complete blockage of GAG deposition, while its addition in the  
228 presence of BMP12/13 resulted in a 26% increase in GAG deposition over 40 days which was  
229 comparable to untreated control cells (Figure 4A).

230

### 231 **Masson's Trichrome**

232 The primary component of tendon matrix is collagen. Masson's trichrome is a convenient stain  
233 in the identification of collagen deposition. Differentiated hESCs revealed distinct cord-like  
234 patterning of collagen deposition after 40 days supplementation with BMP12/13 (Figure 3B).

235 In contrast, control unsupplemented cultures displayed a diffuse faint relatively ubiquitous

236 patterning. Primary rat tenocytes, again included for observation, displayed evidence of a

237 distinct pattern of collagen deposition when compared to differentiated hESC. Over 40 days

238 BMP12/13 supplementation resulted in a 51% increase in collagen deposition vs. 23% for

239 control cultures (Figure 4B). Conversely dorsomorphin supplementation of control cells

240 resulted in a complete block on collagen deposition which was only marginally improved to a

241 10% increase in the presence of BMP12/13.

242

243 **Discussion**

244 *In vitro* tenogenesis is challenging, and the development of simple protocols for its induction  
245 will improve our understanding of tendon biology and the development of future therapies for  
246 tendon treatment. This study demonstrated, for the first time, that a growth supplement cocktail  
247 containing BMP12, BMP13 and AA can induce hESC *in vitro* tenogenic differentiation under  
248 physiologically normoxic (2% O<sub>2</sub>) conditions. Stable transcription of tendon-linked and  
249 specific genes was observed alongside deposition of a tendon-like matrix and elongated,  
250 synapsing, cells with concurrent tenomodulin expression. This represents a forward step in  
251 tenogenesis studies and will facilitate the generation of enhanced *in vitro* studies.

252

253 The definition of a tenocyte is surprisingly complex. The most basic measure is cell phenotype  
254 where the tenocyte is reported frequently as being a long elongated cell which forms cell-cell  
255 connections via synapsing (36,37). Frequently panels of gene expression are used as an  
256 indicative phenotype measure. These can include the  $\alpha$ -chains of collagens type I and III, *DCN*,  
257 *TNC*, and *SCX*, amongst others (33). In this study, we adopted *TNMD* and *THBS4*, alongside  
258 some of the above, following from the findings of Jelinsky et al (12). In their microarray based  
259 studies, they identified *TNMD* and *THBS4* expression as best fitting the definition of tendon  
260 tissue specific in both human and rat tissue. Similar to their study no expression of *SCX* was  
261 noted. We also adopted cellular expression of the tenomodulin protein in association with  
262 synaptic linkage between cells as a measure of tenogenesis (38,39). A combined definition,  
263 drawn from previous publications, of a tenocyte could therefore be an elongated, synaptic, cell  
264 which expresses the genes *TNMD* and *THBS4* and displays positive labelling for the

265 tenomodulin protein in association with cell-cell synapses. In agreement with this, the  
266 combined addition of BMP12, BMP13, and AA, to a basic hESC differentiation media resulted  
267 in a controlled hESC differentiation towards a tenogenic lineage.

268

269 There are relatively few reports of supplement-directed tenogenic differentiation which allow  
270 comparisons to be made. *SCX* expressing, endogenous or ectopic, hESC-MSCs or  
271 hESC-Connective Tissue Progenitors (CTPs) were allowed to become confluent before  
272 being rolled into a sheet and mechanically conditioned for application in an *in vivo* repair model  
273 (10,11,40,41). Histology and mechanical properties of *in vitro* and *in vivo* tissue was consistent  
274 with tendon, but tendon-linked marker gene expression was either lost after 2 weeks *in situ* or  
275 not explored post-transplant and suboptimal regeneration was frequently observed.

276

277 BMP12 and BMP13 signalling are transduced by the BMP Type Ia receptor via  
278 receptor-regulated SMADS (SMAD1, 5 and 8) association with the common mediator,  
279 SMAD4, followed by complex translocation into the nucleus to activate gene transcription  
280 (20,29,42–45). BMP signaling has been suggested to be inhibitory to tendon development by  
281 decreasing the pool of available tendon progenitor cells and restricting tendon-linked gene  
282 expression (40). In this instance, and in agreement with studies documenting an association of  
283 BMP12 and/or 13 with tenogenesis (13,18,19,21–29,44), we noted that BMP12 and BMP13  
284 supplementation was required for maintenance of tendon-specific gene expression including  
285 *TNMD* and *THBS4*. Berasi *et al* similarly found sustained expression of *THSB4* in response to  
286 BMP12/13 supplementation in ectopic tissue in a rat model and a mouse mesenchymal cell

287 line with no evidence of SMAD1, 5 and 8 activation (46). We noted that dorsomorphin, an  
288 inhibitor of BMP signaling, did not inhibit transcription of *TNMD* or *THBS4*, but did inhibit  
289 *COL3A1*, *DCN*, and *TNC* to some extent. This is suggestive of an alternative, BMP-signalling  
290 independent, control of tendon-specific gene expression. It is also notable that although *TNMD*  
291 gene expression was maintained in the presence of dorsomorphin the protein was virtually  
292 undetectable via immunofluorescence, indicating the likelihood of a BMP-signalling driven  
293 translational machinery or key factor in post-translational stability. A deficiency in  
294 extracellular structure or matrix composition was also apparent following on from  
295 dorsomorphin treatment, with significant reduction in matrix-associated GAG, collagen and  
296 elastin. Taken together, these data indicate a complex scenario of BMP signaling requirements  
297 in the development and maintenance of tendon gene expression and tendon tissue.

298

299 In this study, we have demonstrated that hESCs are responsive to tenogenic induction via  
300 BMP12/13 and ascorbic acid supplementation at 2% O<sub>2</sub>. However, the mechanisms by which  
301 BMP12/13 maintain tendon-linked and tendon-specific gene expression and histology remain  
302 unclear, but appear to dissociate into BMP-dependent (*COL3A1*, *DCN*, *TNC*, tenomodulin  
303 immunofluorescence, tendon-like matrix) and BMP-independent (*TNMD* and *THBS4*). These  
304 results will help provide greater insight into BMP12/13 driven tenogenesis of hESC and new  
305 directions of exploration in the design of hESC based treatments for tendon healing.

306



307 **Acknowledgement**

308 We are grateful to the EU Marie Curie Seventh Framework Programme (Grant agreement:  
309 PIRSES-GA-2008-230791), MRC Doctoral Training Fund G0800103, the North Staffordshire  
310 Medical association, the British Orthopaedic Foot and Ankle Society, the American  
311 Orthopaedic Foot and Ankle Society, and Keele University ACORN Fund for supporting this  
312 study.

313

314 **Author Disclosure Statement**

315 No competing financial interests exist.

316

317 **References**

- 318 1. Murchison ND, Price BA, Conner DA, Keene DR, Olson EN, Tabin CJ, et al. Regulation of  
319 tendon differentiation by scleraxis distinguishes force-transmitting tendons from  
320 muscle-anchoring tendons. *Dev. Camb. Engl.* **134**(14), 2697, 2007;
- 321 2. Mendias CL, Bakhurin KI, Faulkner JA. Tendons of myostatin-deficient mice are small,  
322 brittle, and hypocellular. *Proc. Natl. Acad. Sci. U. S. A.* **105**(1), 388, 2008;
- 323 3. Longo UG, Lamberti A, Maffulli N, Denaro V. Tendon augmentation grafts: a systematic  
324 review. *Br. Med. Bull.* **94**, 165, 2010;
- 325 4. Longo UG, Lamberti A, Petrillo S, Maffulli N, Denaro V. Scaffolds in tendon tissue  
326 engineering. *Stem Cells Int.* **2012**, 517165, 2012;
- 327 5. Sharma P, Maffulli N. Tendon injury and tendinopathy: healing and repair. *J. Bone Joint*  
328 *Surg. Am.* **87**(1), 187, 2005;
- 329 6. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al.  
330 Embryonic stem cell lines derived from human blastocysts. *Science.* **282**(5391), 1145,  
331 1998;
- 332 7. Bajada S, Mazakova I, Richardson JB, Ashammakhi N. Updates on stem cells and their  
333 applications in regenerative medicine. *J. Tissue Eng. Regen. Med.* **2**(4), 169, 2008;
- 334 8. Bianco P, Robey PG. Stem cells in tissue engineering. *Nature.* **414**(6859), 118, 2001;
- 335 9. Mimeault M, Hauke R, Batra SK. Stem cells: a revolution in therapeutics-recent advances  
336 in stem cell biology and their therapeutic applications in regenerative medicine and cancer  
337 therapies. *Clin. Pharmacol. Ther.* **82**(3), 252, 2007;
- 338 10. Cohen S, Leshansky L, Zussman E, Burman M, Srouji S, Livne E, et al. Repair of  
339 full-thickness tendon injury using connective tissue progenitors efficiently derived from  
340 human embryonic stem cells and fetal tissues. *Tissue Eng. Part A.* **16**(10), 3119, 2010;
- 341 11. Chen X, Song X-H, Yin Z, Zou X-H, Wang L-L, Hu H, et al. Stepwise differentiation of  
342 human embryonic stem cells promotes tendon regeneration by secreting fetal tendon matrix  
343 and differentiation factors. *Stem Cells Dayt. Ohio.* **27**(6), 1276, 2009;
- 344 12. Jelinsky SA, Archambault J, Li L, Seeherman H. Tendon-selective genes identified from  
345 rat and human musculoskeletal tissues. *J. Orthop. Res.* **28**(3), 289, 2010;
- 346 13. Lee JY, Zhou Z, Taub PJ, Ramcharan M, Li Y, Akinbiyi T, et al. BMP-12 treatment of  
347 adult mesenchymal stem cells in vitro augments tendon-like tissue formation and defect  
348 repair in vivo. *PloS One.* **6**(3), e17531, 2011;

- 349 14. Wang EA, Rosen V, Cordes P, Hewick RM, Kriz MJ, Luxenberg DP, et al. Purification and  
350 characterization of other distinct bone-inducing factors. *Proc. Natl. Acad. Sci. U. S. A.*  
351 **85**(24), 9484, 1988;
- 352 15. Wozney JM. The bone morphogenetic protein family and osteogenesis. *Mol. Reprod. Dev.*  
353 **32**(2), 160, 1992;
- 354 16. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, et al. Novel  
355 regulators of bone formation: molecular clones and activities. *Science.* **242**(4885), 1528,  
356 1988;
- 357 17. Sieber C, Kopf J, Hiepen C, Knaus P. Recent advances in BMP receptor signaling.  
358 *Cytokine Growth Factor Rev.* **20**(5–6), 343, 2009;
- 359 18. Wolfman NM, Hattersley G, Cox K, Celeste AJ, Nelson R, Yamaji N, et al. Ectopic  
360 induction of tendon and ligament in rats by growth and differentiation factors 5, 6, and 7,  
361 members of the TGF-beta gene family. *J. Clin. Invest.* **100**(2), 321, 1997;
- 362 19. Yu Y, Bliss JP, Bruce WJM, Walsh WR. Bone morphogenetic proteins and Smad  
363 expression in ovine tendon-bone healing. *Arthrosc. J. Arthrosc. Relat. Surg. Off. Publ.*  
364 *Arthrosc. Assoc. N. Am. Int. Arthrosc. Assoc.* **23**(2), 205, 2007;
- 365 20. Wang Q-W, Chen Z-L, Piao Y-J. Mesenchymal stem cells differentiate into tenocytes by  
366 bone morphogenetic protein (BMP) 12 gene transfer. *J. Biosci. Bioeng.* **100**(4), 418, 2005;
- 367 21. Lou J, Tu Y, Burns M, Silva MJ, Manske P. BMP-12 gene transfer augmentation of  
368 lacerated tendon repair. *J. Orthop. Res. Off. Publ. Orthop. Res. Soc.* **19**(6), 1199, 2001;
- 369 22. Violini S, Ramelli P, Pisani LF, Gorni C, Mariani P. Horse bone marrow mesenchymal  
370 stem cells express embryo stem cell markers and show the ability for tenogenic  
371 differentiation by in vitro exposure to BMP-12. *BMC Cell Biol.* **10**, 29, 2009;
- 372 23. Dai L, Hu X, Zhang X, Zhu J, Zhang J, Fu X, et al. Different tenogenic differentiation  
373 capacities of different mesenchymal stem cells in the presence of BMP-12. *J. Transl. Med.*  
374 **13**, 200, 2015;
- 375 24. Otabe K, Nakahara H, Hasegawa A, Matsukawa T, Ayabe F, Onizuka N, et al.  
376 Transcription factor Mohawk controls tenogenic differentiation of bone marrow  
377 mesenchymal stem cells in vitro and in vivo. *J. Orthop. Res. Off. Publ. Orthop. Res. Soc.*  
378 **33**(1), 1, 2015;
- 379 25. Li Y, Ramcharan M, Zhou Z, Leong DJ, Akinbiyi T, Majeska RJ, et al. The Role of  
380 Scleraxis in Fate Determination of Mesenchymal Stem Cells for Tenocyte Differentiation.  
381 *Sci. Rep.* **5**, 13149, 2015;
- 382 26. Raabe O, Shell K, Fietz D, Freitag C, Ohrndorf A, Christ HJ, et al. Tenogenic  
383 differentiation of equine adipose-tissue-derived stem cells under the influence of tensile

- 384 strain, growth differentiation factors and various oxygen tensions. *Cell Tissue Res.* **352**(3),  
385 509, 2013;
- 386 27. Gulati BR, Kumar R, Mohanty N, Kumar P, Somasundaram RK, Yadav PS. Bone  
387 morphogenetic protein-12 induces tenogenic differentiation of mesenchymal stem cells  
388 derived from equine amniotic fluid. *Cells Tissues Organs.* **198**(5), 377, 2013;
- 389 28. Shen H, Gelberman RH, Silva MJ, Sakiyama-Elbert SE, Thomopoulos S. BMP12 induces  
390 tenogenic differentiation of adipose-derived stromal cells. *PloS One.* **8**(10), e77613, 2013;
- 391 29. Liu J, Tao X, Chen L, Han W, Zhou Y, Tang K. CTGF positively regulates BMP12  
392 induced tenogenic differentiation of tendon stem cells and signaling. *Cell. Physiol.*  
393 *Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol.* **35**(5), 1831, 2015;
- 394 30. Forsyth NR, Musio A, Vezzoni P, Simpson AHRW, Noble BS, McWhir J. Physiologic  
395 oxygen enhances human embryonic stem cell clonal recovery and reduces chromosomal  
396 abnormalities. *Cloning Stem Cells.* **8**(1), 16, 2006;
- 397 31. Boergemann JH, Kopf J, Yu PB, Knaus P. Dorsomorphin and LDN-193189 inhibit  
398 BMP-mediated Smad, p38 and Akt signalling in C2C12 cells. *Int. J. Biochem. Cell Biol.*  
399 **42**(11), 1802, 2010;
- 400 32. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, et al. Dorsomorphin  
401 inhibits BMP signals required for embryogenesis and iron metabolism. *Nat. Chem. Biol.*  
402 **4**(1), 33, 2008;
- 403 33. Pauly S, Klatte F, Strobel C, Schmidmaier G, Greiner S, Scheibel M, et al. Characterization  
404 of tendon cell cultures of the human rotator cuff. *Eur. Cell. Mater.* **20**, 84, 2010;
- 405 34. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image  
406 analysis. *Nat. Methods.* **9**(7), 671, 2012;
- 407 35. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color  
408 deconvolution. *Anal. Quant. Cytol. Histol.* **23**(4), 291, 2001;
- 409 36. Bernard-Beaubois K, Hecquet C, Houcine O, Hayem G, Adolphe M. Culture and  
410 characterization of juvenile rabbit tenocytes. *Cell Biol. Toxicol.* **13**(2), 103, 1997;
- 411 37. Maffulli N, Ewen SW, Waterston SW, Reaper J, Barrass V. Tenocytes from ruptured and  
412 tendinopathic achilles tendons produce greater quantities of type III collagen than tenocytes  
413 from normal achilles tendons. An in vitro model of human tendon healing. *Am. J. Sports*  
414 *Med.* **28**(4), 499, 2000;
- 415 38. Docheva D, Hunziker EB, Fässler R, Brandau O. Tenomodulin is necessary for tenocyte  
416 proliferation and tendon maturation. *Mol. Cell. Biol.* **25**(2), 699, 2005;

- 417 39. Qi J, Dmochowski JM, Banes AN, Tsuzaki M, Bynum D, Patterson M, et al. Differential  
418 expression and cellular localization of novel isoforms of the tendon biomarker  
419 tenomodulin. *J. Appl. Physiol. Bethesda Md* 1985. **113**(6), 861, 2012;
- 420 40. Chen X, Yin Z, Chen J, Shen W, Liu H, Tang Q, et al. Force and scleraxis synergistically  
421 promote the commitment of human ES cells derived MSCs to tenocytes. *Sci. Rep.*  
422 [Internet]. **2**, 2012 [cited 2017 Mar 26]; Available from:  
423 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3522101/>
- 424 41. Chen X, Yin Z, Chen J-L, Liu H-H, Shen W-L, Fang Z, et al. Scleraxis-overexpressed  
425 human embryonic stem cell-derived mesenchymal stem cells for tendon tissue engineering  
426 with knitted silk-collagen scaffold. *Tissue Eng. Part A*. **20**(11–12), 1583, 2014;
- 427 42. Hoffmann A, Pelled G, Turgeman G, Eberle P, Zilberman Y, Shinar H, et al. Neotendon  
428 formation induced by manipulation of the Smad8 signalling pathway in mesenchymal stem  
429 cells. *J. Clin. Invest.* **116**(4), 940, 2006;
- 430 43. Fu SC, Wong YP, Chan BP, Pau HM, Cheuk YC, Lee KM, et al. The roles of bone  
431 morphogenetic protein (BMP) 12 in stimulating the proliferation and matrix production of  
432 human patellar tendon fibroblasts. *Life Sci.* **72**(26), 2965, 2003;
- 433 44. Wong YP, Fu SC, Cheuk YC, Lee KM, Wong MWN, Chan KM. Bone morphogenetic  
434 protein 13 stimulates cell proliferation and production of collagen in human patellar tendon  
435 fibroblasts. *Acta Orthop.* **76**(3), 421, 2005;
- 436 45. Bi Y, Ehirchiou D, Kilts TM, Inkson CA, Embree MC, Sonoyama W, et al. Identification  
437 of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. *Nat.*  
438 *Med.* **13**(10), 1219, 2007;
- 439 46. Berasi SP, Varadarajan U, Archambault J, Cain M, Souza TA, Abouzeid A, et al.  
440 Divergent activities of osteogenic BMP2, and tenogenic BMP12 and BMP13 independent  
441 of receptor binding affinities. *Growth Factors Chur Switz.* **29**(4), 128, 2011;

442

443 Corresponding author;

444 Professor Nicholas R. Forsyth,

445 The Guy Hilton Research Laboratories,

446 Institute of Science and Technology in Medicine,

447 Faculty of Medicine and Health Sciences,

448 Keele University,

449 Thornburrow Drive,

450 Stoke on Trent, ST4 7QB.

451 UK.

452 email; [n.r.forsyth@keele.ac.uk](mailto:n.r.forsyth@keele.ac.uk)

453 tel; 0044(1)782674388

454

455 Table 1. Tendon-linked gene expression panel.

456


Gene		Primer (5'-3')	Annealing Temp (°C)	Amplicon Size (bp)
COL1A2	F	GACTTTGTTGCTGCTTGC	50	242
	R	CAAGTCCAACCTCCTTTTCC		
COL3A1	F	AAGGACACAGAGGCTTCG	51	210
	R	CTGGTTGACCATCAATGC		
TNMD	F	GCACTGATGAAACATTGG	47	274
	R	ATCCAATACATGGTCAGG		
THBS4	F	CCCCAGGTCTTTGACCTTCTCCC	59	245
	R	ACCTTCCCATCGTTCTTCAGGT		
TNC	F	AAGAGCATTCTGTCAGC	50	217
	R	CAGTTTGCCGGTAAGAGG		
DCN	F	CTGCTTGCACAAGTTTCC	48	372
	R	TTCCAACCTCACC AAAGG		
GAPDH	F	GAGTCAACGGATTTGGTCGT	55	225
	R	GATCTCGCTCCTGGAAGATG		

457 Gene names, primer pair sequences, annealing temperatures, and expected amplicon sizes are  
 458 shown.

459

460

Figure 1



461

Dale et al

462 Figure 1. Tendon-linked gene expression in spontaneously differentiated hESC. Expression of

463 RT-PCR amplified tendon-linked genes including *COL1A2*, *COL3A1*, *DCN*, *TNC*, *THBS4*, and

464 *TNMD* is shown. *GAPDH* is included as an internal control. Primer sequences used are


465 described in Table 1. The left-hand and right-hand panels indicate hESC spontaneously

466 differentiating in 21% O<sub>2</sub> and 2% O<sub>2</sub>, respectively, over days 0, 5, 10 and 20.

467



Figure 2




468

Dale et al

469 Figure 2. BMP12/13 supplementation and 2% O<sub>2</sub> culture promotes stable tenomodulin  
470 expression. A) RT-PCR amplification of the tendon-linked genes described in Figure 1. The  
471 left-hand and right-hand panels indicate hESC differentiating in 2% O<sub>2</sub> with media  
472 supplemented with BMP12/13 or BMP12/13 plus dorsomorphin, respectively at days 5, 10, 20,  
473 and 40. B) Immunofluorescence detection of characteristic tenomodulin protein expression in  
474 primary rat tenocytes. Tenomodulin is green, DAPI (nuclei) is blue. C) Immunofluorescence of  
475 fixed samples paired to A). Colours as described in B). Scale bar indicates 100 μm.  
476

Figure 3




477


Dale et al

478 Figure 3. Matrix compositional changes induced by BMP12/13 supplementation. A) Primary  
479 rat tenocytes (Top panels) and hESC (Bottom panels) with and without BMP12/13  
480 supplementation. Samples were fixed and stained with Alcian blue after 40 days in continuous  
481 culture without passaging. B) Samples matched to 3A) fixed and stained with Masson's  
482 Trichrome. C) Representative image from BMP12/13 supplemented hESC (right hand panel)  
483 indicated shared morphological features with primary rat tenocytes (left hand panel). Scale bar  
484 indicates 200µm.  
485

Figure 4 **A**



**B**



486

Dale et al

487 Figure 4. Dorsomorphin blocks BMP12/13 supplementation-induced matrix deposition in  
 488 hESC. A) ImageJ driven analysis of Alcian blue-stained hESC differentiation over 40 days.  
 489 Y-axis indicates % Blue Channel (RGB extraction) of randomly selected fields of view. X-axis  
 490 indicates Time (days). Solid line indicates hESC, dotted line indicates hESC+dorsomorphin  
 491 (Dorso), dashed line indicates hESC + BMP12/13, and hatched line indicates hESC +  
 492 BMP12/13+Dorso. \* indicates  $p < 0.05$  vs. hESC, \*\* indicates  $p < 0.05$  vs. hESC+Dorso, \*\*\*  
 493 indicates  $p < 0.05$  vs. all. B) ImageJ driven analysis of Masson's Trichrome-stained hESC over  
 494 40 days differentiation. Y-axis indicates % Colour (RGB extraction) of randomly selected  
 495 fields of view. X-axis indicates Time (days). Legend labelling is consistent with (4A) above.  
 496 Error bars indicate standard deviations.  $n=5$  at each time point.

